| 摘要 |
Nitro oleic acid and related metabolites are agonists of PPAR-³. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-³, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-³. |
